^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

KDR expression

i
Other names: VEGFR2, KDR, Vascular Endothelial Growth Factor Receptor 2, Protein-Tyrosine Kinase Receptor Flk-1, Fetal Liver Kinase 1, FLK1, CD309, CD309 Antigen
Entrez ID:
Related biomarkers:
2d
The inhibitory effect of apatinib on different small cell lung cancer cells and in lung cancer-bearing mice and patients. (PubMed, Clin Respir J)
Apatinib has a significant inhibitory effect on small cell lung cancer with high expression of VEGFR2 and may be a treatment for small cell lung cancer patients.
Preclinical • Journal
|
KDR (Kinase insert domain receptor)
|
KDR overexpression • KDR expression
|
AiTan (rivoceranib)
2d
2-Desaza-annomontine (C81) impedes angiogenesis through reduced VEGFR2 expression derived from inhibition of CDC2-like kinases. (PubMed, Angiogenesis)
Surprisingly, alternative splicing of VEGFR2 was not detected. In summary, C81 and other CLK inhibitors could be promising compounds in the treatment of diseases that depend on angiogenesis and inflammation due to their impairment of both processes.
Journal
|
KDR (Kinase insert domain receptor) • CDK1 (Cyclin-dependent kinase 1)
|
KDR expression
7d
VEGFR affects miR-3200-3p-mediated regulatory T cell senescence in tumour-derived exosomes in non-small cell lung cancer. (PubMed, Funct Integr Genomics)
In conclusion, inhibition of VEGFR2 expression in tumour cells promotes the expression of miR-3200-3p in exosomes secreted by tumour cells. miR-3200-3p enters the TME through exosomes and acts on DDB1 in Treg cells to promote senescence of Treg cells to inhibit tumour progression.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • GSTP1 (Glutathione S-transferase pi 1) • DDB1 (Damage Specific DNA Binding Protein 1) • MIR3200 (MicroRNA 3200) • MMP3 (Matrix metallopeptidase 3)
|
KDR expression • DDB1 overexpression
14d
Expression of VEGFR2 Ligand Binding Domain in Pichia pink™ 4 Cells and Evaluation of Its Interactions with VEGF-A165 Receptor Binding Domain. (PubMed, Mol Biotechnol)
4-10 nM concentrations of sKDR1-3 inhibited the proliferation of HUVE cells induced by 5 nM VEGFA165-RBD. In consideration, sKDR1-3 in the nanomolar concentration range, is a promising anticancer drug to inhibit angiogenesis.
Journal
|
KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A)
|
KDR expression
1m
Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer. (PubMed, Transl Oncol)
Mechanistically, the expressions of VEGF, VEGFR2, PDGFR, and FGFR, as well as the phosphorylation levels of AKT, were inhibited after Bev+An treatment. In conclusion, the dual vertical targeting of VEGF and VEGFR in the CRC mice model strongly inhibited tumor growth and angiogenesis, with the suppression of the AKT signaling pathway playing a partial role.
Journal
|
FGFR (Fibroblast Growth Factor Receptor) • KDR (Kinase insert domain receptor) • ANXA5 (Annexin A5)
|
KDR expression • VEGFA expression
|
Avastin (bevacizumab) • Focus V (anlotinib)
1m
Development of novel indazolyl-acyl hydrazones as antioxidant and anticancer agent that target VEGFR-2 in human breast cancer cells. (PubMed, Chem Biodivers)
In silico docking study revealed the favorable binding energies of -7.30 kcal/mol and -8.04 kcal/mol for compounds towards Vascular Endothelial Growth Factor Recaptor-2 (VEGFR-2), respectively. In conclusion, we have synthesized antioxidant and anticancer agents that target VEGFR-2 in breast cancer cells.
Journal
|
KDR (Kinase insert domain receptor)
|
KDR overexpression • KDR expression
1m
Apatinib weakens proliferation, migration, invasion, and angiogenesis of thyroid cancer cells through downregulating pyruvate kinase M2. (PubMed, Sci Rep)
In summary, Apatinib has a regulatory role in TC progression, and Apatinib can block cancer cell angiogenesis by downregulating PKM2. This will provide a theoretical basis for therapy of TC.
Journal
|
KDR (Kinase insert domain receptor) • CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • PKM (Pyruvate Kinase M1/2)
|
KDR expression • CDH1 expression • VIM expression
|
AiTan (rivoceranib)
2ms
Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis. (PubMed, Laryngoscope)
Our analysis shows that RRP tissue shows elevated levels of multiple immune check point targets and VEGFR3, with varied patterns unique to each papilloma patient. Some of these immune checkpoint markers already have novel immunotherapies available or in development, providing molecular rationale to offer these systemic treatments to selected patients affected by RRP alongside VEGF inhibitors. Laryngoscope, 2024.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A) • LAG3 (Lymphocyte Activating 3) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • FLT4 (Fms-related tyrosine kinase 4) • LGALS9 (Galectin 9)
|
PD-L1 expression • PD-1 expression • CD8 expression • LAG3 expression • HAVCR2 expression • KDR expression • PD-1 elevation • TIGIT expression • PD-L2 expression
2ms
Hepatitis B Virus-Encoded MicroRNA (HBV-miR-3) Inhibits FIH-1 Expression to Promote Tumor Angiogenesis in HBV-Related Hepatocellular Carcinoma. (PubMed, J Hepatocell Carcinoma)
HBV-miR-3 was related to HCC patients' overall survival and it promoted angiogenesis by repressing FIH-1 expression. HBV-miR-3 may be a new marker for predicting prognosis and a novel target for anti-angiogenic treatment of HBV-related HCC.
Journal
|
KDR (Kinase insert domain receptor) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
KDR expression • HIF1A expression
2ms
VE-cadherin junction dynamics in initial lymphatic vessels promotes lymph node metastasis. (PubMed, Life Sci Alliance)
We conclude that VEGFA mediates zippering of VE-cadherin junctions in initial lymphatics. Zippering is accompanied by increased VE-cadherin fragmentation through VEGFA-induced Src kinase activation, correlating with tumor dissemination to sentinel lymph nodes.
Journal
|
CDH5 (Cadherin 5)
|
EGFR mutation • VEGFA elevation • KDR expression • KDR mutation
2ms
Journal
|
KDR (Kinase insert domain receptor) • NOS3 (Nitric oxide synthase 3)
|
KDR expression • VEGFA expression
|
Caprelsa (vandetanib)
2ms
VEGFR2 Expression Correlates with Postnatal Development of Brain Arteriovenous Malformations in a Mouse Model of Type I Hereditary Hemorrhagic Telangiectasia. (PubMed, Biomedicines)
We employed SclCreER(+);Eng mice, enabling timed Eng gene deletion in endothelial cells via tamoxifen...VEGFR2 expression peaked in the initial 2 postnatal weeks, coinciding with BAVM onset. These findings support the "second hit" theory, highlighting the role of early postnatal angiogenesis in initiating BAVM development in HHT type I mice.
Preclinical • Journal
|
KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A) • ENG (Endoglin)
|
KDR expression
|
tamoxifen
2ms
Transcription Factor FOSL1 Promotes Angiogenesis of Colon Carcinoma by Regulating the VEGF Pathway Through Activating TIMP1. (PubMed, Biochem Genet)
FOSL1 activated VEGF pathway by up-regulating TIMP1 expression, thereby advancing CC angiogenesis. We provided theoretical basis that the FOSL1/TIMP1/VEGF pathway might be a novel option for anti-angiogenesis therapy of CC.
Journal
|
KDR (Kinase insert domain receptor) • FLT4 (Fms-related tyrosine kinase 4) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • FOSL1 (FOS Like 1)
|
KDR expression • FOSL1 expression • VEGFA expression • KIM1 expression • TIMP1 expression
3ms
In vivo antiangiogenic effect of nimbolide, trans-chalcone and piperine for use against glioblastoma. (PubMed, BMC Cancer)
Taken together, NBL, TC and PPR can suppress U87-induced neoangiogenesis via a reduction in VEGF-A and its receptor VEGFR-2 transcript expression at noncytotoxic concentrations. These phytochemicals showed their utility as adjuvants to GBM therapy, with Piperine demonstrating superior effectiveness among them all.
Preclinical • Journal
|
KDR (Kinase insert domain receptor)
|
VEGFA elevation • KDR expression
3ms
Low-dose Cisplatin Induces Tumor Growth via Mobilization of Proangiogenic Bone Marrow-derived Cells in Mouse Models. (PubMed, Anticancer Res)
These results indicate that metronomic CDDP promoted tumor angiogenesis and tumor growth via increased mobilization of proangiogenic BMDCs at certain low doses. This implies a potential therapeutic risk from an inappropriate LDM chemotherapy dosage and suggests that optimizing the LDM chemotherapy regimen is urgently needed.
Preclinical • Journal
|
KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • MMP9 (Matrix metallopeptidase 9) • CDH5 (Cadherin 5)
|
KDR expression • CDH1 expression • FLT1 expression
|
cisplatin
3ms
BR55 Ultrasound Molecular Imaging of Clear Cell Renal Cell Carcinoma Reflects Tumor Vascular Expression of VEGFR-2 in a Patient-Derived Xenograft Model. (PubMed, Int J Mol Sci)
Mice were divided into four groups to receive either vehicle or axitinib an amount of 2, 7.5 or 15 mg/kg twice daily...Significant Pearson correlation coefficients were observed between the area under the curve (AUC) and the CD34 (0.84, p < 10), and between the VEGFR-2-specific signal obtained by USMI and IHC (0.72, p < 10). USMI with BR55 could provide instant, quantitative information on tumor VEGFR-2 expression to characterize renal masses non-invasively.
Preclinical • Journal
|
KDR (Kinase insert domain receptor) • CD34 (CD34 molecule)
|
KDR expression
|
Inlyta (axitinib)
3ms
Gastric tubular adenocarcinoma with diffuse neutrophils infiltrating: characteristics and probable treatment strategy. (PubMed, Gastric Cancer)
TADNI is a special morphological subtype with poorer prognoses and unique molecular characteristics, which might benefit from CXCR1/CXCR2 inhibitors.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • KDR (Kinase insert domain receptor) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • MIR223 (MicroRNA 223)
|
PD-L1 expression • HER-2 expression • CD8 expression • CD8 positive • KDR expression
3ms
High Level of Adropin Promotes the Progression of Pancreatic Ductal Adenocarcinoma. (PubMed, Curr Cancer Drug Targets)
Adropin overexpression in PDA promotes cancer cell proliferation and angiogenesis in tumor microenvironment by continuously activating VEGFR2 signaling, thereby creating conditions for tumor progression. Thus, targeting adropin may be an effective anti-PDA strategy.
Journal
|
CCND1 (Cyclin D1) • MMP2 (Matrix metallopeptidase 2)
|
CCND1 expression • KDR expression
3ms
Dihydroartemisinin inhibits melanoma migration and metastasis by affecting angiogenesis. (PubMed, Phytother Res)
DHA inhibits melanoma invasion and metastasis by mediating angiogenesis. These results have important implications for the potential use of DHA in treatment of melanoma.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
KDR expression • CD31 expression
3ms
Low EGFL7 expression is associated with high lymph node spread and invasion of lymphatic vessels in colorectal cancer. (PubMed, Sci Rep)
Finally, we found in silico that EGFL7 expression was associated with cell growth, angiogenesis, and important pathways such as VEGF, Rap-1, MAPK and PI3K/Akt. Expression of EGFL7 in tumor cells may be associated with important pathways that can alter functions related to tumor invasive processes, preventing recurrence and metastatic process.
Journal
|
KDR (Kinase insert domain receptor) • PI3K (Phosphoinositide 3-kinases)
|
KDR expression
4ms
Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study. (PubMed, BMC Cancer)
It was validated that GLS1 was a sensitive and specific biomarker for pathological diagnosis of HCC and had prognostic value, thus having practical value for clinical application.
Journal
|
KDR (Kinase insert domain receptor) • AFP (Alpha-fetoprotein) • GPC3 (Glypican 3) • GLS1 (Glutaminase)
|
KDR expression • GPC3 expression • AFP expression
4ms
Osmundacetone Inhibits Angiogenesis of Infantile Hemangiomas through Inducing Caspases and Reducing VEGFR2/MMP2. (PubMed, Anticancer Agents Med Chem)
OSC demonstrated promising results in inhibiting HemECs' proliferation, inducing apoptosis, and ameliorating pathological changes in hemangiomas in mice. Moreover, it influenced the expression of crucial caspases and angiogenesis-related proteins. These findings suggest that OSC holds potential as a novel drug for clinical treatment of IH.
Journal • PARP Biomarker
|
KDR (Kinase insert domain receptor) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • FADD (Fas associated via death domain) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • MMP9 (Matrix metallopeptidase 9)
|
KDR expression • BAX expression • CASP3 elevation • MMP9 elevation
4ms
Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. (PubMed, Int J Cancer)
Progression-free survival was not reached yet. Apa+ddTCb regimen achieved an improved efficacy and acceptable adverse events compared with ddTCb regimen, which might be a promising strategy in the neoadjuvant therapy for locally advanced TNBC.
Journal • Metastases
|
EGFR (Epidermal growth factor receptor) • KDR (Kinase insert domain receptor)
|
EGFR expression • KDR expression • VEGFA expression
|
carboplatin • paclitaxel • AiTan (rivoceranib)
4ms
Effect of sunitinib against Echinococcus multilocularis through inhibition of VEGFA-induced angiogenesis. (PubMed, Parasit Vectors)
SU11248 is a potential candidate drug for the treatment of AE, which predominantly inhibits parasite-induced angiogenesis. Host-targeted anti-angiogenesis treatment strategies constitute a new avenue for the treatment of AE.
Journal
|
IL4 (Interleukin 4)
|
KDR expression • VEGFA expression • IL4 elevation
|
Sutent (sunitinib)
4ms
VEGFR2-specific CAR-T cells show improved tumor infiltration in syngeneic mouse glioma models (SNO 2023)
VEGFR2-CAR-T cells show improved glioma infiltration in syngeneic mouse models. Therefore, VEGFR2 might be a relevant target that could improve CAR-T cell infiltration in glioblastoma.
Preclinical • CAR T-Cell Therapy
|
KDR (Kinase insert domain receptor)
|
KDR expression
4ms
TiO nanoparticles promote tumor metastasis by eliciting pro-metastatic extracellular vesicles. (PubMed, J Nanobiotechnology)
Mechanically, miR-301a-3p derived from NPs-elicited EVs could be delivered into vascular endothelial cells, which inhibited the expression of VEGFR2 and VE-cadherin by targeting S1PR1, leading to disrupt the tight junctions of vascular endothelial cells, thus to promote vascular permeability and angiogenesis, and induce the formation of pre-metastasis niches in vivo. This study emphasizes that it is urgent to consider the effect of NPs on EVs under long-term use conditions when designing nanodrugs for cancer treatment.
Journal • Metastases
|
KDR (Kinase insert domain receptor) • CDH5 (Cadherin 5) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
|
KDR expression • CDH1 expression
4ms
Kaposi's sarcoma-associated herpesvirus viral protein kinase augments cell survival. (PubMed, Cell Death Dis)
Treatment of HUVEC-vPK cells with a pan-AKT inhibitor Miransertib (ARQ 092) reduced the overall phosphorylation of AKT, resulting in the cleavage of Caspase-3 and the induction of apoptosis. vPK expression also inhibited the cytotoxicity of cisplatin in vitro and in vivo. Collectively, our findings demonstrate that vPK's ability to augment cell survival and promote angiogenesis is critically dependent on AKT signaling, which is relevant for future therapies for treating KSHV-associated cancers.
Journal
|
CASP3 (Caspase 3) • AKT2 (V-akt murine thymoma viral oncogene homolog 2)
|
KDR expression • VEGFA expression
|
cisplatin • miransertib (MK-7075)
4ms
Pseudogene MAPK6P4-encoded functional peptide promotes glioblastoma vasculogenic mimicry development. (PubMed, Commun Biol)
Finally, we used orthotopic and subcutaneous xenografted nude mouse models of GBM to verify the inhibitory effect of the above factors on GBM VM development. In summary, this study may represent new targets for the comprehensive treatment of glioma.
Journal
|
LDHA (Lactate dehydrogenase A) • KDR (Kinase insert domain receptor) • CDH5 (Cadherin 5)
|
KDR expression
4ms
Deletion of Endothelial TRPV4 Protects Heart From Pressure Overload-Induced Hypertrophy. (PubMed, Hypertension)
Our results suggest that endothelial TRPV4 acts as a mechanical break for coronary angiogenesis, and uncoupling endothelial TRPV4 mechanotransduction attenuates pathological cardiac hypertrophy by enhancing coronary angiogenesis.
Journal
|
KDR (Kinase insert domain receptor) • FGF2 (Fibroblast Growth Factor 2) • NOS3 (Nitric oxide synthase 3) • TRPV4 (Transient Receptor Potential Cation Channel Subfamily V Member 4)
|
KDR expression
5ms
Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma. (PubMed, J Hepatol)
Hypoxia-induced EC-specific DGKG hyper-expression promotes tumor angiogenesis and immune evasion via the ZEB2/TGF-β1 axis, suggesting EC-specific DGKG as a potential therapeutic target for HCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
KDR (Kinase insert domain receptor) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • TGFB1 (Transforming Growth Factor Beta 1) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2) • USP1 (Ubiquitin Specific Peptidase 1)
|
KDR expression
5ms
Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer. (PubMed, Front Immunol)
Immunotherapy plus single-agent chemotherapy as a second- or later-line treatment is safe, effective, and tolerable for metastatic NSCLC. EV markers can be used as predictive markers of efficacy in patients with metastatic NSCLC treated with immunotherapy plus chemotherapy to help monitor treatment efficacy and guide treatment decisions.
Retrospective data • Journal • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase) • KDR (Kinase insert domain receptor)
|
EGFR expression • KDR expression
5ms
Beta IV spectrin inhibits the metastatic growth of melanoma by suppressing VEGFR2-driven tumor angiogenesis. (PubMed, Cancer Med)
Intraperitoneally injected B16 cells formed larger tumors with increased tumor vessel density and greater propensity for metastatic spread particularly to the chest cavity and lung compared to control mice. These results support β -spectrin as a key regulator of tumor angiogenesis and a viable vascular target in cancer.
Journal • Metastases
|
KDR (Kinase insert domain receptor)
|
KDR expression
5ms
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial. (PubMed, BMC Cancer)
Supported by a solid rationale, the trial has the potential to generate milestone data about the synergistic effects of cabozantinib plus lanreotide in a group of NET patients with relatively aggressive disease and limited therapeutic options.
P2 data • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • AXL (AXL Receptor Tyrosine Kinase) • KDR (Kinase insert domain receptor) • SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
KDR expression
|
Cabometyx (cabozantinib tablet) • Somatuline Depot (lanreotide prolonged-release subcutaneous)
5ms
A Vegfr2-Specific Car T Cells With Anti-Glioma And Anti-Angiogenic Activity Against Glioblastoma (EANO 2023)
Our dataset demonstrates that VEGFR2-CAR T cells prolong the survival of glioma-bearing mice through anti-glioma and anti-glioma vasculature activity. The results suggest that the magnitude of the vasculature-targeting activity depends on vessel-density within the tumor. VEGFR2 might be a relevant target that could be exploited for a novel CAR T cell-based immunotherapeutic approach against glioblastoma.
CAR T-Cell Therapy • IO biomarker
|
KDR (Kinase insert domain receptor)
|
KDR expression
6ms
Vascular Endothelial Growth Factor-D (VEGF-D): An Angiogenesis Bypass in Malignant Tumors. (PubMed, Int J Mol Sci)
Owing to its high mitogenic ability, higher affinity for VEGFR-2, and higher expression in cancer, VEGF-D might even be a stronger angiogenic driver and, hence, a better therapeutic target than VEGF-A. In this review, we summarized the angiogenic role of VEGF-D in blood vasculogenesis and its targetability as an antiangiogenic therapy in cancer.
Review • Journal
|
KDR (Kinase insert domain receptor) • VEGFD (Vascular Endothelial Growth Factor D)
|
KDR expression • VEGFA expression
6ms
Hsa-miR-503-5p regulates CTDSPL to accelerate cisplatin resistance and angiogenesis of lung adenocarcinoma cells. (PubMed, Chem Biol Drug Des)
Hsa-miR-503-5p bound to CTDSPL gene and promoted cisplatin resistance and malignant progression of LUAD cells by negatively regulating CTDSPL. Our results revealed that hsa-miR-503-5p and CTDSPL may be novel targets for overcoming cisplatin resistance in LUAD.
Journal
|
KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • MIR503 (MicroRNA 503)
|
KDR expression • VEGFA expression • FLT1 expression • miR-503 expression
|
cisplatin
6ms
Hesperidin suppressed metastasis, angiogenesis and tumour growth in Balb/c mice model of breast cancer. (PubMed, J Cell Mol Med)
Survival of tumour-bearing mice was the highest in mice receiving a combination of hesperidin and doxorubicin (Dox) (80%) compared to the normal saline (43%), hesperidin 5 (54%), 10 (55.5%), 10 (60.5%) and 40 (66%) mg/kg, and 10 mg/kg Dox-treated (73%) groups (p < 0.0001 for all)...Immunohistochemical staining showed significant reductions in Ki-67 (p < 0.001) and VEGF (p < 0.001) and a significant elevation in E-cadherin (p = 0.005) in the 10 mg/kg Dox + 20 mg/kg treatment group than in 10 mg/kg Dox alone group. Hesperidin can be considered as a potentially suitable anti-cancer agent for BC that can synergize with other chemotherapeutics.
Preclinical • Journal
|
KDR (Kinase insert domain receptor) • IFNG (Interferon, gamma) • CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • ENG (Endoglin) • IL4 (Interleukin 4)
|
IFNG expression • KDR expression
|
doxorubicin hydrochloride
6ms
Chimeric antigen receptor macrophages activated through TLR4 or IFN-γ receptors suppress breast cancer growth by targeting VEGFR2. (PubMed, Cancer Immunol Immunother)
Implantation of these CAR-Ms into 4T1 breast cancer-bearing mice could obviously inhibit the progression of tumor without significant toxic side effects, especially the group of mmC in which constructed with Tlr4 as the intracellular domain of CAR. In conclusion, this research provides a promising design of CAR that induce macrophages activation by Tlr4 and/or Ifn-γ receptors, and these CAR-Ms could effectively inhibit tumor growth through targeting VEGFR2.
Journal • IO biomarker
|
KDR (Kinase insert domain receptor) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • TLR4 (Toll Like Receptor 4) • CD86 (CD86 Molecule)
|
KDR expression
6ms
Targeting glioblastoma multiforme using a novel fusion protein comprising interleukin-13 and staphylococcal enterotoxin B in vitro. (PubMed, Toxicol In Vitro)
The expression of MMP2, MMP9 and VEGFR2 in U251 cells experienced a significant reduction after treatment with IL13-linker-SEB compared to SEB and T98G treated cells. The data showed that IL13-linker-SEB can be considered as a novel potential agent for GBM treatment; however, further research is needed to investigate the efficacy.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • KDR (Kinase insert domain receptor) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • MMP9 (Matrix metallopeptidase 9) • IL13 (Interleukin 13)
|
KDR expression
6ms
YAP/STAT3 inhibited CD8 T cells activity in the breast cancer immune microenvironment by inducing M2 polarization of tumor-associated macrophages. (PubMed, Cancer Med)
In conclusion, this study suggested inhibition of YAP/STAT3 reversed M2 polarization of TAMs and suppressed CD8 T-cell activity in the BC immune microenvironment. These findings open up new avenues for the development of innovative therapies in the treatment of BC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • KDR (Kinase insert domain receptor) • YAP1 (Yes associated protein 1) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1)
|
PD-L1 expression • PD-L1 overexpression • KDR expression
6ms
Expression of angiogenic and lymphangiogenic genes in primary cutaneous melanoma: relationship with angiolymphatic invasion and disease-free survival. (PubMed, Melanoma Res)
Our main results suggest that LYVE-1 gene expression is closely related to ALI; the relationship with the development of metastases in MM deserves further studies. Low expression of VEGFR2 was associated with disease progression and the expression of VEGFR2 correlates with an increased DFS.
Journal
|
KDR (Kinase insert domain receptor) • LYVE1 (Lymphatic vessel endothelial hyaluronan receptor 1)
|
KDR expression